Philippe Amouyel
Full Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Alzheimer’s disease (AD) is characterized by a strong genetic predisposition and by an early loss of synaptic connectivity that strongly correlates with cognitive deficit. Some genetic determinants could contribute to synapse frailty toward AD pathology. However, the role of genetic determinants in AD pathogenesis remains poorly understood at the synaptic level. Here, we show that the expression of an isoform of the major AD susceptibility gene BIN1 in the presynaptic compartment results in synaptic loss. Using electrophysiology, we observed an early loss of synaptic transmission upon BIN1 isoform 1 (BIN1iso1) expression in Drosophila retinal photoreceptor neurons. This was not observed for the other human BIN1 isoforms tested, isoform 8 and isoform 9. Structural analysis of photoreceptor neuron synapses shows a strong accumulation of abnormally large vesicles in the presynaptic compartment, reminiscent of this same isoform-induced endosome defects in cell bodies. In addition, the expression of BIN1iso1 in motoneurons of the Drosophila neuromuscular junction alters the morphology of synaptic boutons, with a greater number and a smaller size of synaptic boutons, and the appearance of satellite boutons. As opposed to endosomal defects in cell body, modulating the Rab11 recycling endosome regulator did not prevent BIN1iso1 synaptotoxicity. To test if synaptic deficits are conserved in a mammalian model and to assert a presynaptic vs postsynaptic role for BIN1, we used rat primary neurons cultured in microfluidic devices that restrict gene expression modulation in particular neuron populations. We found a loss of synaptic connectivity only when expressing BIN1iso1 in the presynaptic compartment, which was confirmed by microelectrode array analysis. Together, our results suggest that BIN1 expression in the presynaptic terminal, but not the postsynaptic terminal leads to an isoform-specific, deleterious effect on synaptic integrity. BIN1 synaptotoxicity could contribute to the synapse loss observed early in AD. This supports the idea that genetic determinants could make synapses prone to failure in AD.
Year:
2025
Background Chatbots have demonstrated promising capabilities in medicine, scoring passing grades for board examinations across various specialties. However, their tendency to express high levels of confidence in their responses, even when incorrect, poses a limitation to their utility in clinical settings. Objective The aim of the study is to examine whether token probabilities outperform chatbots’ expressed confidence levels in predicting the accuracy of their responses to medical questions. Methods In total, 9 large language models, comprising both commercial (GPT-3.5, GPT-4, and GPT-4o) and open source (Llama 3.1-8b, Llama 3.1-70b, Phi-3-Mini, Phi-3-Medium, Gemma 2-9b, and Gemma 2-27b), were prompted to respond to a set of 2522 questions from the United States Medical Licensing Examination (MedQA database). Additionally, the models rated their confidence from 0 to 100, and the token probability of each response was extracted. The models’ success rates were measured, and the predictive performances of both expressed confidence and response token probability in predicting response accuracy were evaluated using area under the receiver operating characteristic curves (AUROCs), adapted calibration error, and Brier score. Sensitivity analyses were conducted using additional questions sourced from other databases in English (MedMCQA: n=2797), Chinese (MedQA Mainland China: n=3413 and Taiwan: n=2808), and French (FrMedMCQA: n=1079), different prompting strategies, and temperature settings. Results Overall, mean accuracy ranged from 56.5% (95% CI 54.6‐58.5) for Phi-3-Mini to 89% (95% CI 87.7‐90.2) for GPT-4o. Across the United States Medical Licensing Examination questions, all chatbots consistently expressed high levels of confidence in their responses (ranging from 90, 95% CI 90-90 for Llama 3.1-70b to 100, 95% CI 100-100 for GPT-3.5). However, expressed confidence failed to predict response accuracy (AUROC ranging from 0.52, 95% CI 0.50‐0.53 for Phi-3-Mini to 0.68, 95% CI 0.65‐0.71 for GPT-4o). In contrast, the response token probability consistently outperformed expressed confidence for predicting response accuracy (AUROCs ranging from 0.71, 95% CI 0.69‐0.73 for Phi-3-Mini to 0.87, 95% CI 0.85‐0.89 for GPT-4o; all P <.001). Furthermore, all models demonstrated imperfect calibration, with a general trend toward overconfidence. These findings were consistent in sensitivity analyses. Conclusions Due to the limited capacity of chatbots to accurately evaluate their confidence when responding to medical queries, clinicians and patients should abstain from relying on their self-rated certainty. Instead, token probabilities emerge as a promising and easily accessible alternative for gauging the inner doubts of these models.
Year:
2025
Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.
Year:
2025
We developed a high content screening to investigate how Alzheimer disease (AD) genetic risk factors may impair synaptic mechanisms in rat primary neuronal cultures. Out of the gene targets identified, we found that shRNA-mediated downregulation of Plcg2 in mouse dentate gyrus neurons consistently impaired dendritic morphology and synaptic function. In human neuronal cultures (hNCs), PLCG2 downregulation also impaired synaptic function and was associated with increased levels of Aβ and Tau phosphorylation, potentially via the AKT/GSK3β axis. Very rare PLCG2 loss-of-functon(LoF) variants were associated with a 10-fold increased AD risk. PLCG2 LoF carriers exhibit low mRNA/protein PLCG2/PLCγ2 levels, consistent with nonsense-mediated mRNA decay mechanisms. Restoring PLCγ2 levels in shPLCG2-hNCs fully reversed the disease-related phenotypes. Our findings indicate that the downregulation of PLCγ2 increases the risk of AD by impairing synaptic function and increasing the levels of Aβ and Tau phosphorylation in neurons.
Year:
2024
Bridging Integrator 1 ( BIN1 ) is the second most important Alzheimer’s disease (AD) risk gene, but its physiological roles in neurons and its contribution to brain pathology remain largely elusive. In this work, we show that BIN1 plays a critical role in the regulation of calcium homeostasis, electrical activity, and gene expression of glutamatergic neurons. Using single-cell RNA-sequencing on cerebral organoids generated from isogenic BIN1 wild type (WT), heterozygous (HET) and homozygous knockout (KO) human-induced pluripotent stem cells (hiPSCs), we show that BIN1 is mainly expressed by oligodendrocytes and glutamatergic neurons, like in the human brain. Both BIN1 HET and KO cerebral organoids show specific transcriptional alterations, mainly associated with ion transport and synapses in glutamatergic neurons. We then demonstrate that BIN1 cell-autonomously regulates gene expression in glutamatergic neurons by using a novel protocol to generate pure culture of hiPSC-derived induced neurons (hiNs). Using this system, we also show that BIN1 plays a key role in the regulation of neuronal calcium transients and electrical activity via its interaction with the L-type voltage-gated calcium channel Cav 1.2 . BIN1 KO hiNs show reduced activity-dependent internalization and higher Cav 1.2 expression compared to WT hiNs. Pharmacological blocking of this channel with clinically relevant doses of nifedipine, a calcium channel blocker, partly rescues electrical and gene expression alterations in BIN1 KO glutamatergic neurons. Further, we show that transcriptional alterations in BIN1 KO hiNs that affect biological processes related to calcium homeostasis are also present in glutamatergic neurons of the human brain at late stages of AD pathology. Together, these findings suggest that BIN1 -dependent alterations in neuronal properties could contribute to AD pathophysiology and that treatment with low doses of clinically approved calcium blockers should be considered as an option to slow disease-onset and progression.
Year:
2024
Collaborators (59)
Ruth Frikke-Schmidt
Professor, Chief Physician, MD PhD DMSc
-
Pau Pastor
Institut Català de la Salut
Eloy Rodriguez-Rodríguez
Instituto de Investigación Marqués de Valdecilla
innocenzo rainero
University of Turin
Agustín Ruiz Laza
Director of the Biology Core
University of Texas Health Science Center at San Antonio
Jesper Qvist Thomassen
Senior Scientist
Rigshospitalet
Henne Holstege
Professor
KU Leuven
Marco Spallazzi
Adjunt professor
University of Parma
Benedetta Nacmias
University of Florence
Lucilla Parnetti
Professor of Neurology
University of Perugia
Caroline Jonson
University of California, San Francisco
Jordi Pérez-Tur
Coordinador Adjunto al Área Global Vida
Agencia Estatal Consejo Superior de Investigaciones Científicas
Patrizia Mecocci
Director
Karolinska Institutet
Caroline Graff
Professor,MD PhD
Karolinska Institutet
Henna Martiskainen
University of Eastern Finland
Patrik Verstreken
Group Leader, Director and Professor
KU Leuven
Amy Kit Yu Fu
Research Professor
The Hong Kong University of Science and Technology
Arvid Rongve
Professor
University of Bergen
Jean-Charles Lambert
Head of research unit
INSERM
Nancy Yuk-Yu Ip
The Morningside Professor of Life Science
The Hong Kong University of Science and Technology
Katja Scheffler
Associate Professor
Norwegian University of Science and Technology
Julien Chapuis
Université de Lille
Takeshi Ikeuchi
Professor
Brain Research Institute, Niigata University
Geir Selbaek
Professor
University of Oslo
Aarno Palotie
University of Helsinki
Pablo Mir
-
Tormod Fladby
Professor ll of Neurology
University of Oslo
Frank Lafont
Director
CNRS Délégation Nord Pas-de-Calais et Picardie
Srdjan Djurovic
Senior Researcher
University of Oslo
Sami Heikkinen
Research Director
University of Eastern Finland
Najaf Amin
Associate Professor
University of Oxford
Wiesje van der Flier
Scientific director
VU medisch centrum
Peter Holmans
Professor of Biostatistics and Genetic Epidemiology
Cardiff University
Marcos R. Costa
Lab Head/Professor
Federal University of Rio Grande do Norte
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
Alessio Squassina
Dalhousie University
Carole Dufouil
Director of research
INSERM
Martin Ingelsson
Specialist
Uppsala University Hospital
Hilkka Soininen
Kuopio University Hospital
Gael Nicolas
PUPH
University of Rouen
Devrim Kilinc
Institut Pasteur de Lille
Anssi Lipponen
University of Eastern Finland
Claudio Queiroz
Associate Professor
Federal University of Rio Grande do Norte
Avishek Roy
Karolinska Institutet
Patrick Kehoe
Academic , Gestetner Professor of Translational Dementia Research
University of Bristol
Alfredo Ramirez
University of Texas Health Science Center at San Antonio
INGVILD SALTVEDT
Professor
Norwegian University of Science and Technology
Dag Aarsland
Professor and Head of Department
King’s College London
Daniela Galimberti
Associate Professor
Università degli Studi di Torino
Ole A. Andreassen
Oslo University Hospital
Lucio Tremolizzo
Associate Professor of Neurology
University of Milano-Bicocca
Valentina Escott-Price
Professor
Cardiff University
Ville Leinonen
Professor
University of Eastern Finland
Rebecca Sims
Senior Research Fellow
Cardiff University
Simon Mead
Deputy Director
University College London
Barbara Borroni
Docenti di ruolo di IIa fascia
University of Brescia
Jose Luis Royo
University of Malaga
Mikko Hiltunen
University of Eastern Finland
Julia TCW
Assistant Professor, Director
Boston University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.